Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan;5(1):93-4.
doi: 10.1177/1758834012469430.

Tegafur-uracil (UFT) in lower doses is safe for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle

Daniel I G Cubero  1 , Auro Del Giglio
Affiliations

Tegafur-uracil (UFT) in lower doses is safe for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle

Daniel I G Cubero et al. Ther Adv Med Oncol. 2013 Jan.
No abstract available

PubMed Disclaimer

References

    1. Carmichael J., Popiela T., Radstone D., Falk S., Borner M., Oza A., et al. (2002) Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3617–3627 - PubMed
    1. Cubero D., Cruz F., Santi P., Silva I., Del G. (2012) Tegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle. Ther Adv Med Oncol 4: 167–172 - PMC - PubMed
    1. Deenen M., Terpstra W., Cats A., Boot H., Schellens J. (2010) Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine. Ann Intern Med 153: 767–768 - PubMed
    1. Deenen M., Cats A., Beijnen J., Schellens J. (2013) Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients Ther Adv Med Oncol 5, 91–92 - PMC - PubMed
    1. Douillard J., Hoff P., Skillings J., Eisenberg P., Davidson N., Harper P., et al. (2002) Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 17: 3605–3616 - PubMed

LinkOut - more resources